Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.52 |
| ▸ | CTSD | P07339 | 6/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241197 | 0.87 | BACE1 (0.54) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL8237934 | 0.87 | BACE1 (0.54) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL4526519 | 0.85 | BACE1 (0.70) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL4520508 | 0.83 | BACE1 (0.66) | BACE1BACE2CTSD | |
| SCHEMBL4526528 | 0.82 | BACE1 (0.64) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL4912050 | 0.79 | BACE1 (0.69) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL4109037 | 0.79 | BACE1 (0.76) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL4735682 | 0.79 | BACE1 (0.59) | BACE1BACE2CTSDAPPREN | |
| SCHEMBL4528752 | 0.78 | BACE1 (0.58) | BACE1BACE2CTSD | |
| SCHEMBL4228426 | 0.78 | BACE1 (0.69) | BACE1BACE2CTSDAPPREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | BACE1 14/4885BACE2 30/4885CTSD 3413/4885 |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | BACE1 14/4885BACE2 30/4885CTSD 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.